Hepatitis C viral dynamics and immune activation in HCV / HIV co-infected patients during treatment with pegylated interferon alpha-2a and ribavirin.

Trial Profile

Hepatitis C viral dynamics and immune activation in HCV / HIV co-infected patients during treatment with pegylated interferon alpha-2a and ribavirin.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Dec 2012

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C; HIV infections
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 05 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top